[go: up one dir, main page]

SK8092001A3 - Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor - Google Patents

Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor Download PDF

Info

Publication number
SK8092001A3
SK8092001A3 SK809-2001A SK8092001A SK8092001A3 SK 8092001 A3 SK8092001 A3 SK 8092001A3 SK 8092001 A SK8092001 A SK 8092001A SK 8092001 A3 SK8092001 A3 SK 8092001A3
Authority
SK
Slovakia
Prior art keywords
pharmaceutical formulation
active substance
solid pharmaceutical
hmg
pravastatin
Prior art date
Application number
SK809-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Janez Kerc
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Publication of SK8092001A3 publication Critical patent/SK8092001A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
SK809-2001A 1998-12-16 1999-10-29 Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor SK8092001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9800309A SI20109A (sl) 1998-12-16 1998-12-16 Stabilna farmacevtska formulacija
PCT/IB1999/001749 WO2000035425A1 (fr) 1998-12-16 1999-10-29 FORMULATION PHARMACEUTIQUE STABLE COMPRENANT UN INHIBITEUR DE HMG-CoA REDUCTASE

Publications (1)

Publication Number Publication Date
SK8092001A3 true SK8092001A3 (en) 2001-10-08

Family

ID=20432372

Family Applications (1)

Application Number Title Priority Date Filing Date
SK809-2001A SK8092001A3 (en) 1998-12-16 1999-10-29 Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor

Country Status (25)

Country Link
US (3) US6680341B1 (fr)
EP (2) EP1911445A3 (fr)
JP (1) JP2002532409A (fr)
KR (1) KR100638307B1 (fr)
CN (1) CN1198597C (fr)
AT (1) ATE380020T1 (fr)
AU (1) AU775946B2 (fr)
BG (1) BG105559A (fr)
CA (1) CA2348988C (fr)
CZ (1) CZ302562B6 (fr)
DE (1) DE69937691T2 (fr)
ES (1) ES2299265T3 (fr)
HR (1) HRP20010325A2 (fr)
HU (1) HUP0104258A3 (fr)
IL (2) IL143759A0 (fr)
IS (1) IS5939A (fr)
NZ (1) NZ511260A (fr)
PL (1) PL347686A1 (fr)
RU (1) RU2227019C2 (fr)
SI (2) SI20109A (fr)
SK (1) SK8092001A3 (fr)
TR (1) TR200101235T2 (fr)
WO (1) WO2000035425A1 (fr)
YU (1) YU35501A (fr)
ZA (1) ZA200103802B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6558659B2 (en) 2000-04-10 2003-05-06 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
DE60041281D1 (de) † 2000-06-09 2009-02-12 Lek Pharmaceuticals Stabilisiertes arzneimittel und arzneizubereitung
PL362764A1 (en) * 2000-06-09 2004-11-02 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US20050215636A1 (en) * 2000-10-05 2005-09-29 Vilmos Keri Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
CA2442280A1 (fr) * 2001-03-27 2002-10-03 Ranbaxy Laboratories Limited Composition pharmaceutique stable a base de pravastatine
GB0111077D0 (en) * 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
CA2449998A1 (fr) * 2001-06-21 2003-01-03 Andrx Pharmaceuticals, Inc. Compositions pharmaceutiques a liberation controlee, stables, contenant de la pravastatine
JP2003055217A (ja) * 2001-08-10 2003-02-26 Taiyo Yakuhin Kogyo Kk 医薬組成物
EP1905431A1 (fr) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Formulations pharmaceutiques de pravastatine et leurs procédés d'utilisation
MXPA04006780A (es) 2002-01-11 2005-06-08 Athpharma Ltd Formulaciones farmaceuticas de pravastatina y metodos para usarlas.
IL163550A0 (en) * 2002-02-14 2005-12-18 Ranbaxy Lab Ltd Formulations of atorvastatin stabilized with alkali metal additions
CA2385529A1 (fr) * 2002-05-21 2003-11-21 Bernard Charles Sherman Formulations posologiques stables contenant de l'atorvastatin calcium
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
CA2497896A1 (fr) * 2002-09-03 2004-03-18 Biovail Laboratories Inc. Formulations pharmaceutiques de pravastatin et leurs modes d'utilisation
JP2006512359A (ja) * 2002-12-20 2006-04-13 ファイザー・プロダクツ・インク ＣＥＴＰ阻害薬及びＨＭＧ−ＣｏＡ還元酵素阻害薬を含有する剤形
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
EP1737449A1 (fr) * 2004-03-01 2007-01-03 LEK Pharmaceuticals D.D. Composition pharmaceutique
KR100598326B1 (ko) 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
WO2006008757A2 (fr) * 2004-05-05 2006-01-26 Cadila Healthcare Limited Compositions pharmaceutiques stabilisees contenant de la pravastatine
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
US7642287B2 (en) * 2004-08-06 2010-01-05 Transform Pharmaceuticals, Inc. Statin pharmaceutical compositions and related methods of treatment
US20090149533A1 (en) * 2004-08-06 2009-06-11 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
AU2005305460B2 (en) * 2004-11-22 2011-04-21 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
US20060229277A1 (en) * 2005-04-08 2006-10-12 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
CA2615941A1 (fr) * 2005-08-05 2007-02-15 Orbus Pharma Inc. Compositions pharmaceutiques a liberation prolongee, stabilisees, comprenant un inhibiteur de l'hmg-coa reductase
US20090247603A1 (en) 2005-12-23 2009-10-01 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP1810667A1 (fr) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique contenant de l'atorvastatin amorphé
US20080038332A1 (en) * 2006-08-10 2008-02-14 Cai Gu Huang Stable pharmaceutical formulation comprising atorvastatin calcium
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
WO2008062476A2 (fr) * 2006-10-31 2008-05-29 Glenmark Pharmaceutical Limited Composition pharmaceutique comprenant de la rosuvastatine ou un sel de qualité pharmaceutique de cette substance
BG934U1 (bg) * 2006-12-14 2007-11-30 "Софарма" Ад Състав за твърда лекарствена форма, съдържащ правастатин
US20100196469A1 (en) * 2007-06-25 2010-08-05 Pharmathen S.A. Pharmaceutical Formulation containing an HMG-COA Reductase Inhibitor and method for the preparation thereof
GB0713707D0 (en) * 2007-07-13 2007-08-22 Generics Uk Ltd Stable compositions
WO2009024889A2 (fr) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Composition pharmaceutique comprenant un inhibiteur de réductase hmg-coa et un ézétimibe
DE102007052071A1 (de) 2007-10-30 2009-05-07 Stada Arzneimittel Ag Stabilisiertes Atorvastatin
JPWO2011049122A1 (ja) * 2009-10-21 2013-03-14 第一三共株式会社 プラバスタチンナトリウム口腔内速崩壊錠及びその製造方法
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
TR201005326A2 (tr) 2010-06-30 2012-01-23 B�Lg�� Mahmut Çoklu dozaj formları.
JP5829607B2 (ja) * 2010-06-30 2015-12-09 持田製薬株式会社 ω３脂肪酸の配合製剤
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
WO2012141160A1 (fr) * 2011-04-12 2012-10-18 沢井製薬株式会社 Préparation contenant de la pitavastatine et son procédé de production
WO2012153181A1 (fr) * 2011-05-11 2012-11-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique comprenant de la pitavastatine ou ses sels pharmaceutiquement acceptables
WO2012170417A2 (fr) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Procédés et compositions pour améliorer la croissance osseuse comprenant une statine
EP2779999A2 (fr) 2011-11-15 2014-09-24 Dr. Reddy's Laboratories Ltd. Formulations pharmaceutiques comprenant de l'atorvastatine et du glimépiride
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
EP3184103A1 (fr) 2015-12-21 2017-06-28 Hexal AG Composition pharmaceutique comprenant de l'atorvastatine ou un sel de celui-ci
CN109044989A (zh) * 2018-10-09 2018-12-21 河南师范大学 一种阿托伐他汀钙胶囊制剂及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US579837A (en) * 1897-03-30 Saw-sharpening machine
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
ATE178794T1 (de) * 1993-01-19 1999-04-15 Warner Lambert Co Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
NZ286920A (en) * 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
SK282991B6 (sk) * 1995-12-22 2003-01-09 Kowa Company, Ltd. Stabilizovaná farmaceutická kompozícia na báze kyseliny (E)- 3,5-dihydroxy-7-[4'-4''-fluórfenyl-2'-cyklopropylchinolin-3'yl]- 6-hepténovej
FR2751316B1 (fr) * 1996-07-19 1998-08-28 Granger Maurice Appareil distributeur de bandes de papier ouate pour essuie-mains, papier toilette et similaire
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
PL362764A1 (en) * 2000-06-09 2004-11-02 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
TW589178B (en) * 2003-02-21 2004-06-01 China Chemical & Pharmaceutica A novel industrial process to obtain pravastatin sodium of high purity

Also Published As

Publication number Publication date
WO2000035425A1 (fr) 2000-06-22
YU35501A (sh) 2005-07-19
AU6360899A (en) 2000-07-03
AU775946B2 (en) 2004-08-19
HRP20010325A2 (en) 2002-06-30
BG105559A (en) 2001-12-29
US20040072894A1 (en) 2004-04-15
DE69937691T2 (de) 2008-11-20
IL143759A0 (en) 2002-04-21
SI20109A (sl) 2000-06-30
RU2227019C2 (ru) 2004-04-20
EP1911445A3 (fr) 2011-04-27
DE69937691D1 (de) 2008-01-17
IL143759A (en) 2006-08-01
EP1911445A2 (fr) 2008-04-16
CN1330538A (zh) 2002-01-09
SI1148872T1 (sl) 2008-04-30
US20090264497A1 (en) 2009-10-22
EP1148872B1 (fr) 2007-12-05
CA2348988C (fr) 2009-07-21
CA2348988A1 (fr) 2000-06-22
ZA200103802B (en) 2002-06-10
CZ302562B6 (cs) 2011-07-13
KR20010101105A (ko) 2001-11-14
KR100638307B1 (ko) 2006-10-25
JP2002532409A (ja) 2002-10-02
TR200101235T2 (tr) 2001-10-22
EP1148872A1 (fr) 2001-10-31
PL347686A1 (en) 2002-04-22
CN1198597C (zh) 2005-04-27
ATE380020T1 (de) 2007-12-15
HUP0104258A3 (en) 2002-11-28
NZ511260A (en) 2004-01-30
HUP0104258A2 (hu) 2002-03-28
IS5939A (is) 2001-05-15
CZ20011727A3 (cs) 2001-09-12
US6680341B1 (en) 2004-01-20
ES2299265T3 (es) 2008-05-16

Similar Documents

Publication Publication Date Title
SK8092001A3 (en) Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
EP1292293B1 (fr) Composition stabilisee pharmaceutiquement efficace et preparation pharmaceutique comprenant cette composition
AU2000249434A1 (en) Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
IL104041A (en) Pharmaceutical compositions comprising an hmg-CoA reductase inhibitor compound and method for their preparation
CA2692862C (fr) Compositions stables
SI21400A (sl) Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze
US6806290B2 (en) Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
EP1296672B2 (fr) Produit et preparation pharmaceutiques stables
CA2385529A1 (fr) Formulations posologiques stables contenant de l'atorvastatin calcium